Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not a subscriber? Subscribe now for unlimited access to online articles.

Rewriting Life

Infinite Drug Diversity

New chemical-synthesis methods help researchers build more varied and complex drug candidates.

The genomics revolution has provided innumerable potential targets for new drugs. But many of these disease-causing proteins seem to be “undruggable”: companies can’t find compounds that inhibit them. Into this breach comes Boston startup Infinity Pharmaceuticals, which plans to use new chemical-synthesis methods to build more varied and complex drug candidates than have previously been possible.

Infinity’s technique, pioneered by Harvard University chemist and company cofounder Stuart Schreiber, involves binding simple starting compounds to hosts of small plastic supports. The compounds acquire new chemical groups as they are exposed to a series of carefully chosen solutions; the supports are separated at various steps, producing smaller collections bearing unique chemicals. Such reactions are easier to track than those performed in solution and can yield a wide variety of products.

Infinity’s pedigree is impressive. Richard Klausner, former head of the National Cancer Institute, and Eric Lander, the cofounder of genomics pioneer Millennium Pharmaceuticals, are scientific advisors. Steven Holtzman, Millennium’s longtime chief financial officer, says he left to become president and CEO of Infinity because “I felt that perfecting that biological revolution required a revolution in chemistryAnd I felt this platform had the best chance.”

This story is part of our July/August 2002 Issue
See the rest of the issue
Subscribe

Infinity is focusing first on drugs for diabetes, inflammation, cancer and bacterial infections. “At the very least, it will be a more diverse set of compounds to test,”says Brent Stockwell, a chemist at the Whitehead Institute for Biomedical Research in Cambridge, MA. “But perhaps they’ll even be better.” That would give drugmakers a cornucopia to rival the biologists’.

Become an MIT Technology Review Insider for in-depth analysis and unparalleled perspective.

Subscribe today
More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to MIT Technology Review.
  • Print + All Access Digital {! insider.prices.print_digital !}* Best Value

    {! insider.display.menuOptionsLabel !}

    The best of MIT Technology Review in print and online, plus unlimited access to our online archive, an ad-free web experience, discounts to MIT Technology Review events, and The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Unlimited access to all our daily online news and feature stories

    6 bi-monthly issues of print + digital magazine

    10% discount to MIT Technology Review events

    Access to entire PDF magazine archive dating back to 1899

    Ad-free website experience

    The Download: newsletter delivered daily

  • All Access Digital {! insider.prices.digital !}*

    {! insider.display.menuOptionsLabel !}

    The digital magazine, plus unlimited site access, our online archive, and The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Unlimited access to all our daily online news and feature stories

    Digital magazine (6 bi-monthly issues)

    Access to entire PDF magazine archive dating back to 1899

    The Download: newsletter delivered daily

  • Print Subscription {! insider.prices.print_only !}*

    {! insider.display.menuOptionsLabel !}

    Six print issues per year plus The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Print magazine (6 bi-monthly issues)

    The Download: newsletter delivered daily

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.